Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1548"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
"Enzyme system: human liver microsomes
NADPH added: yes
inhibitor used: n/a
reaction: beta-OH-lovastatin-->6'-exomethylene-lovastatin
Quote:
Lovastatin was metabolized by human liver microsomes to two major metabolites: 6'beta-hydroxy [Michaelis-Menten constant (Km): 7.8 +/- 2.7 microM] and 6'-exomethylene lovastatin (Km,10.3 +/- 2.6 microM). 6'beta-Hydroxylovastatin formation in the liver was inhibited by the specific CYP3A inhibitors cyclosporine (Ki, 7.6 +/- 2.3 microM), ketoconazole (Ki, 0.25 +/- 0.2 microM), and troleandomycin (Ki, 26.6 +/- 18.5 microM).
NOTE: though the authors do note clearly state it, they do mention that lovastatin is completely converted to its "open acid" form which we in the DIKB infer to be beta-OH-lovastatin"
|
| dc:creator | |
| dc:date |
"09/28/2007 13:28:09"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ beta-hydroxy-lovastatin_has_metabolite_6'-exomethylene-lovastatin, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1065 }